Compare DexCom, Inc. (DXCM) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ProShares Ultra QQQ ETF — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while ProShares Ultra QQQ ETF trades at $98.55 (market cap $15.38B). The key difference: DexCom, Inc. is far larger — about 2.1× ProShares Ultra QQQ ETF's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| DXCM | QLD | |
|---|---|---|
Market Cap | $31.86B | $15.38B |
Volume | 3,607,070 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.34 | $100.77 |
52-Week Low | $54.84 | $57.16 |
Typical Hold Time | 62 Days | 36 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
QLD, the ProShares Ultra QQQ ETF, trades at $98.43, down 1.8% on the day, with a bullish technical signal driven by moving averages. The ETF aims to deliver twice the daily return of the Nasdaq-100 Index. Recent news highlights its resilience compared to higher-leverage counterparts during market downturns, with institutional buying noted in Q2 2026.
The outlook hinges on Nasdaq-100 performance and Federal Reserve policy, with support at $96 and resistance at $100. Risks include market volatility and leverage decay. Analyst sentiment is mixed, advising caution until technical confirmation above key moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
